Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Venetoclax Combined With Azacytidine as Maintenance Therapy Post Allogeneic Hematopoietic Stem Cell Transplantation in Myelodysplastic Syndromes and Acute Myeloid Leukemia

NCT06598384 is registered in ClinicalTrials.gov with Navy General Hospital, Beijing as lead sponsor.

NCT NCT06598384
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06598384 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Venetoclax Combined With Azacytidine as Maintenance Therapy Post Allogeneic Hematopoietic Stem Cell Transplantation in Myelodysplastic Syndromes and Acute Myeloid Leukemia
Lead sponsor
Navy General Hospital, Beijing
Phase
Phase 2
Overall status
Not yet recruiting
Start date
September 30, 2024
Completion date
September 30, 2030
Enrollment
40 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

acute myeloid leukemia